抗腫瘤生物製劑：在成長市場中成功的策略

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

Introduction

Biological agents are essential tools in cancer treatment, particularly as antitumor drugs. Unsurprisingly, current R&D in this therapeutic area therefore focuses on antitumor agents, predominantly MAbs. While the market is robust-anticancer biologics garnered $9.5 billion in 2005-and expanding, the future for such high-cost drugs is fraught with competitive and fi nancial challenges.

Get the Answers You Need to Shape Your Strategy

Monoclonal antibodies, generating $7.3 billion in sales in 2005, have been the most successful class of biological anticancer agents. What does the future hold for anticancer MAbs? Genentech' s Herceptin (trastuzumab) recently traversed a clinical path from approval in a small percentage of breast cancer patients to broader use as an early-stage treatment. How can MAbs and other biologics expand into new indications? How can agents leverage off-label use into new approvals and thus vastly expand sales potential? Third-party payers and patients have expressed concern over the high cost of anticancer biologics, denying off-label use or forgoing treatment altogether. What impact will reimbursement issues have on developing agents? Emerging agents may place pricing pressures on currently marketed antitumor therapies. How can companies protect the value of current agents? What approaches will manufacturers take to ensure that new drugs will be embraced in the clinic?

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Introduction
• Existing Biologic Antitumor Agents
• Monoclonal Antibodies
• Rituxan
• Herceptin
• Avastin
• Recombinant Cytokines
• Targeted Cytotoxins and Radiological Agents
• Emerging Antitumor Biologics
• Panitumumab
• Pertuzumab
• Galiximab
• Volociximab
• Mapatumumab
• CAT-3888
• CDP-791
• Herceptin: A Model for Expanding an Agent' s Reach
• Reimbursement Concerns with Anticancer Biologics
• Outlook

Tables

• 1. Select Antitumor Biologic Therapeutic Approaches
• 2. Current Antitumor Protein Drugs, 2006
• 3. Select Emerging Antitumor Biologic Agents, 2006
• 4. Early Stage Approaches to Biological Cancer Treatment
• 5. Critical Clinical Trial Results for Herceptin

Figures

• 1. Antibody Structure
• 2. Number of Anticancer Biologics on the Market, 1995-2006

相關商品

抗體和免疫相關市場調查報告書

大腸癌、血管增生、抗體分析
Triple Analysis: Colorectal Cancer, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

白血病、血管增生、抗體：藥劑開發策略分析
Triple Analysis: Leukemia, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

淋巴癌、血管增生、抗體：藥劑開發策略分析
Triple Analysis: Lymphoma, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

Decision Resources, Inc.發行的生物科技相關市場調查報告書

以生物標記來預測自體免疫疾病生物療法的反應

Special Report: Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases

價格 : US $ 9200

出版日期 : 2011年06月

成為下一波一鳴驚人藥物的新一代治療用抗體的尋求

Pursuing Next-Generation Therapeutic Antibodies as the Next Source of Blockbuster Drugs

價格 : US $ 4600

出版日期 : 2011年06月

探索讓個人化醫療進化的資訊技術工具

Exploiting Information Technology Tools to Advance Personalized Medicine

價格 : US $ 4600

出版日期 : 2011年05月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!